Brand Name: Taficita
Composition:
Emtricitabine – 200 mg
Tenofovir Disoproxil Fumarate (TDF) – 25 mg
Form: Tablet
Strength: 200 mg / 25 mg
Packaging Type: Bottle
Packaging Size: 1 Bottle (typically 30 tablets per bottle)
Manufacturer: Mylan Laboratories Ltd
Minimum Order Quantity: 1 Bottle
Country of Origin: India
Prescription Required: Yes
Taficita Tablet is a fixed-dose combination antiretroviral medication used in the treatment of HIV-1 infection. It contains Emtricitabine and Tenofovir Disoproxil Fumarate (TDF), two potent nucleoside reverse transcriptase inhibitors (NRTIs). These active ingredients work together to block the replication of the HIV virus, thereby lowering viral load and enhancing immune function.
Taficita is typically used in combination with other antiretroviral agents as part of combination antiretroviral therapy (cART) or pre-exposure prophylaxis (PrEP), depending on clinical recommendation.
HIV-1 infection in adults and adolescents
May also be used as part of HIV PrEP (Pre-Exposure Prophylaxis) regimens (consult physician)
Dual-action NRTI formulation
Trusted formulation from Mylan, a leading global pharmaceutical company
Supports viral suppression and reduces risk of HIV progression
Enhances CD4+ cell counts
Convenient once-daily oral dose
Brand Name: Taficita
Composition:
Emtricitabine – 200 mg
Tenofovir Disoproxil Fumarate (TDF) – 25 mg
Form: Tablet
Strength: 200 mg / 25 mg
Packaging Type: Bottle
Packaging Size: 1 Bottle (typically 30 tablets per bottle)
Manufacturer: Mylan Laboratories Ltd
Minimum Order Quantity: 1 Bottle
Country of Origin: India
Prescription Required: Yes
Taficita Tablet is a fixed-dose combination antiretroviral medication used in the treatment of HIV-1 infection. It contains Emtricitabine and Tenofovir Disoproxil Fumarate (TDF), two potent nucleoside reverse transcriptase inhibitors (NRTIs). These active ingredients work together to block the replication of the HIV virus, thereby lowering viral load and enhancing immune function.
Taficita is typically used in combination with other antiretroviral agents as part of combination antiretroviral therapy (cART) or pre-exposure prophylaxis (PrEP), depending on clinical recommendation.
HIV-1 infection in adults and adolescents
May also be used as part of HIV PrEP (Pre-Exposure Prophylaxis) regimens (consult physician)
Dual-action NRTI formulation
Trusted formulation from Mylan, a leading global pharmaceutical company
Supports viral suppression and reduces risk of HIV progression
Enhances CD4+ cell counts
Convenient once-daily oral dose